↓ Skip to main content

Access to medicines for diabetes treatment in Brazil: evaluation of “health has no price” program

Overview of attention for article published in Diabetology & Metabolic Syndrome, May 2016
Altmetric Badge


3 Dimensions

Readers on

29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Access to medicines for diabetes treatment in Brazil: evaluation of “health has no price” program
Published in
Diabetology & Metabolic Syndrome, May 2016
DOI 10.1186/s13098-016-0150-8
Pubmed ID

João Leopoldo Oliveira Araujo, João Leopoldo Oliveira Araujo, Mariana Donato Pereira, Cristiane Bergamaschi, Fernando Sá Del Fiol, Luciane Cruz Lopes, Maria Inês Toledo, Silvio Barberato-Filho


In 2011, private pharmacies associated to the Brazilian Ministry of Health provided patients with two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg glibenclamide and 500 and 850 mg metformin) free of charge. The aim was to evaluate the impact of the "Health Has No Price" Program [Saúde Não Tem Preço (SNTP)] for access to diabetes treatment medicines in Brazil. This longitudinal and observational study is based on the number of units of oral hypoglycemic agents, insulin and insulin analogues supplied in 55,000 private pharmacies from February 1, 2010 to January 31, 2012. The number of tablets (oral hypoglycemic agents) and international units (insulins and insulin analogues) supplied in the first 12 months of the SNTP Program were compared with the number of tablets and international units supplied in the 12 months prior to its implementation. The insulins in the SNTP program had the highest percentage change in the number of international units supplied; regular human insulin increased by 97.8 % and isophane insulin (NPH) by 78.0 %. Among the oral hypoglycemic agents, 5 mg glibenclamide increased by 65.9 %, and 500 and 850 mg metformin increased by 46.8 and 39.9 %, respectively, in the number of tablets dispensed in the first year of the SNTP Program. Among the hypoglycemic agents not available in SNTP, 4 mg glimepiride had the highest percentage increase in units supplied (19.2 %) in the same period. Among the insulin analogues, which were not available in the SNTP Program, insulin glulisine showed the greatest increase in units dispensed (34.2 %). The SNTP Program contributed to increased access to medicines for the treatment of diabetes in Brazil.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 34%
Researcher 7 24%
Student > Bachelor 3 10%
Professor 2 7%
Student > Doctoral Student 2 7%
Other 1 3%
Unknown 4 14%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 9 31%
Medicine and Dentistry 5 17%
Economics, Econometrics and Finance 3 10%
Nursing and Health Professions 2 7%
Social Sciences 2 7%
Other 3 10%
Unknown 5 17%